Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595025 | 0.84 | KDM4E (0.53) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13595021 | 0.82 | TSHR (0.50) | ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL8806635 | 0.81 | KDM4E (0.42) | ALDH1A1SMN1; SMN2KDM4EGAAHSD17B10 | |
| SCHEMBL7743909 | 0.81 | L3MBTL1 (0.61) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL27458779 | 0.81 | HRH4 (0.59) | ALDH1A1MAPTKDM4EGAALMNA | |
| SCHEMBL31137919 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL5717618 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL16588903 | 0.78 | TLR8 (0.59) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL4228872 | 0.78 | KDM4E (0.61) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL5789220 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | disclosed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-5663179-A | CAN SENSITIZE MULTIDRUG RESISTANT CANCER CELLS TO CHEMOTHERAPEUTIC AGENTS | LABORATOIRES GLAXO SA (FR) | 1997-09-02 | — | — | US | disclosed |
| EP-0649410-B1 | ANILIDE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0649410-A1 | ANILIDE DERIVATIVES. | GLAXO LAB SA (FR) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994001408-A1 | ANILIDE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | ALDH1A1 3166/4885MAPT 3998/4885SMN1; SMN2 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.